Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NCEL) Decreases By 62.7%

NLS Pharmaceutics Ltd. (NASDAQ:NCEL) was the target of a large drop in short interest in the month of March. As of March 13th, there was short interest totaling 36,007 shares, a drop of 62.7% from the February 26th total of 96,641 shares. Based on an average daily trading volume, of 28,526 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.9% of the company’s shares are short sold. Currently, 0.9% of the company’s shares are short sold. Based on an average daily trading volume, of 28,526 shares, the days-to-cover ratio is currently 1.3 days.

NLS Pharmaceutics Stock Performance

Shares of NLS Pharmaceutics stock opened at $2.42 on Wednesday. The business has a 50 day moving average of $2.68 and a 200 day moving average of $7.27. NLS Pharmaceutics has a 52 week low of $1.89 and a 52 week high of $30.80.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.